Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793998 | 0.98 | LMNA (0.56) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL22725674 | 0.95 | LMNA (0.52) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL12376561 | 0.82 | CHRM1 (0.40) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL2611016 | 0.82 | NPSR1 (0.44) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL11457672 | 0.82 | CHRM1 (0.56) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL23842148 | 0.80 | CHRM1 (0.39) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL12794005 | 0.80 | ALDH1A1 (0.47) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL23641952 | 0.80 | LMNA (0.52) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL24428834 | 0.79 | CHRM1 (0.38) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL24429015 | 0.79 | NOS3 (0.43) | LMNACHRM1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2019079596-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019079485-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | Epizyme, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| CN-1038410-C | Butynelamine derivative | NIPPON SHINYAKU CO LTD (JP) | 1998-05-20 | — | — | CN | disclosed |
| CN-1041582-A | BUTYNELAMINE DERIVATIVE | NIPPON SHINYAKU CO LTD (JP) | 1990-04-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | LMNA 4658/4885CHRM1 4757/4885CHRM2 4616/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | LMNA 2568/4885CHRM1 4880/4885CHRM2 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.